Showing 1571-1580 of 2101 results for "".
- TOPICAL SKIN Launches Antioxidant Face Oilhttps://modernaesthetics.com/news/topical-skin-launches-antioxidant-face-oil/2476145/Skincare brand TOPICAL SKIN launched Phyto AOX Face Oil N°10, a plant-based facial oil developed to protect the skin from environmental damage such as pollution, UV rays, and blue light. The formula features a proprietary Exposome Defense Technology, describ
- Alma Introduces PixelPeel™ Laser Peel for Minimal-Downtime Skin Renewalhttps://modernaesthetics.com/news/alma-introduces-pixelpeel-laser-peel-for-minimal-downtime-skin-renewal/2476137/Alma has launched PixelPeel™, a new fractional laser peel treatment designed for subtle, controlled skin resurfacing with minimal recovery time. The treatment is compatible with the Alma Pixel™ and Alma Hybrid® platforms and uses the company’s MotionSync™ technology to deliver uniform exfoliation
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie
- ProRx Highlights Role of 503B Outsourcing in Patient-Centered Wellness Carehttps://modernaesthetics.com/news/prorx-highlights-role-503b-outsourcing-patient-centered-wellness-care/2476084/In recognition of National Wellness Month, ProRx, an FDA-registered 503B outsourcing facility, is emphasizing the clinical value of personalized, high-quality compounded therapies in wellness-focused care models. ProRx provides sterile and non-sterile compounded medications for office use
- Regenerative Dermatology Company Forms Strategic Manufacturing Partnership with Innovigenhttps://modernaesthetics.com/news/regenerative-dermatology-company-forms-strategic-manufacturing-partnership-with-innovigen/2476008/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell-powered skincare, has entered a strategic manufacturing partnership with Innovigen, a California-based formulation and production company specializing in cosmetic GMP manufacturing. The agreement represents a
- Merz Aesthetics Names New US Sales and Marketing Leadershttps://modernaesthetics.com/news/merz-aesthetics-names-new-us-sales-and-marketing-leaders/2475952/Merz Aesthetics has appointed Chris Van Dyk as Vice President of US Sales and DJ Sethares as Vice President of US Marketing, the company announced. Both executives will lead commercial functions across the US to support growth of the company’s aesthetics portfolio. Van Dyk previously serve
- Alma Launches AI-Assisted Skincare System with Nearly 12M Formulation Optionshttps://modernaesthetics.com/news/alma-launches-ai-assisted-skincare-system-with-nearly-12m-formulation-options/2475858/Alma has launched Universkin by Alma, a new AI-assisted medical-grade skincare platform designed to support physicians in offering personalized treatment regimens. The system enables rapid clinical assessment and tailored formulation of topical therapies using an intelligent diagnostic algorithm
- Obagi Medical Acquires Novaestiq to Introduce HA Injectables in US Markethttps://modernaesthetics.com/news/obagi-medical-acquires-novaestiq-to-introduce-ha-injectables-in-us-market/2475814/Obagi Medical is set to expand into aesthetic injectables following the acquisition of Novaestiq Corp., the company behind the Saypha® ChIQ™ and Saypha® MagIQ™ hyaluronic acid (HA) filler products. The transaction was completed by Obagi’s parent company, Waldencast
- Global Botulinum Toxins Market Projected to Reach $15.7 Billion by 2030https://modernaesthetics.com/news/global-botulinum-toxins-market-projected-to-reach-157-billion-by-2030/2475785/The global market for botulinum toxin products is expected to grow from $8.9 billion in 2025 to $15.7 billion by 2030, according to new projections from MarketsandMarkets, representing a compound annual growth rate (CAGR) of 11.7%. This sustained growth is attributed to increased global de
- CollPlant Appoints Bowman Bagley to Lead North American Commercial Operationshttps://modernaesthetics.com/news/collplant-appoints-bowman-bagley-to-lead-north-american-commercial-operations/2475724/CollPlant Biotechnologies has appointed Bowman Bagley as Vice President, Commercial North America, a newly established role aimed at expanding the company’s commercial presence and operations in the region. Bagley will oversee sales, marketing, lo